Rebounding with Strength: AI Innovation, Health Care Tools and Sports Legacy Drive MDCE’s Expansion
MESA, AZ / ACCESS Newswire / August 22, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is entering a major rebound phase in 2025, marked by rapid growth and innovation across its subsidiaries. The company reported that Q2 revenue surged by over 2,500% year-over-year, with momentum continuing into Q3 where performance is on pace to exceed those results.
At the core of MDCE’s resurgence is its proprietary AI imaging system, now patent-pending (U.S. Provisional Patent Application No. 63/854,935). This groundbreaking technology enhances medical diagnostic imaging while also powering AI-driven authentication for high-value collectibles, showcasing the company’s ability to bridge healthcare and culture through applied innovation.
MDCE’s Three Growth Engines:
Medical Care Technologies – Developing smartphone-based AI diagnostic tools for real-time healthcare monitoring and early disease detection.
Real Game Used – Delivering AI-powered authentication and photo-match verification for sports and entertainment memorabilia.
Infinite Auctions – A premier auction house currently featuring “The Grail Collection”, an unprecedented offering of historic memorabilia including iconic game-worn items from Michael Jordan and other legends.
“2025 represents a true turning point for MDCE,” said Marshall Perkins III, CEO of Medical Care Technologies Inc.“With our patent-pending technology and the explosive growth of our subsidiaries, we’re scaling aggressively in healthcare and collectibles while creating sustainable long-term value for shareholders.”
For more information, visit www.mdcestock.com, www.infiniteauctions.com, www.realgameused.com.
Safe Harbor Statement
This release may contain forward-looking statements subject to risks and uncertainties. Actual results may differ materially, and the Company assumes no obligation to update these statements.
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…